logo
logo
Sign in

Adult Malignant Glioma Therapeutics Market: Increasing Healthcare Spending Will Propel Growth

avatar
ankit pittewar

Increasing Prevalence of malignant glioma is a key factor driving the adult malignant glioma therapeutics market, says Fortune Business Insights in a report, titled “Adult Malignant Glioma Therapeutics Market Size, Share and Industry Analysis Product By Therapy (Chemotherapy, Radiotherapy, Targeted therapy) By Disease (Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma) By End User, and Regional Forecast 2019-2026.” The global adult malignant glioma therapeutics market size was valued at USD 1,459.1 Million in 2018, is projected to reach USD 2,964.5 Million by the end of 2026, exhibiting a CAGR of 9.3%.

Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/adult-malignant-glioma-therapeutics-market-100572

Leading Players operating in the Adult Malignant Glioma Therapeutics Market are:

Key players are involved in mergers and acquisition to strengthen their market position. Owing to increasing competition frequent innovations are taking place in the market. Some of the companies operating the industry are:

  • Merck & Co., Inc.
  • Hoffmann-La Roche Ltd
  • Arbor Pharmaceuticals
  • Pfizer Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol-Myers Squibb Company
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Novocure

Government Regulatory Policies Will Favor Growth 

The increasing advancements in imaging technologies have led to early detection of the disease. This factor is expected to accelerate the growth of the market. The regulatory policies and government support for the development of novel therapies is likely to boost the market growth.  The increasing R&D investment by key players for the development of glioma therapies will create growth opportunities for the market. Furthermore, the targeted therapies segment is predicted to account for high shares during the forecast period owing to the advancement in drug development which, results in the successful applications of targeted therapies to improve the survival rate. Targeted therapies are commonly used in the treatment of gliomas such as EGFR-targeted therapies, which target the tyrosine kinases receptors and others. In terms of end-user, the hospital segment will account for maximum shares during the forecast period owing to the increasing patient population and high hospital admissions

 

For more information in the analysis of this report, visit: https://www.fortunebusinessinsights.com/industry-reports/adult-malignant-glioma-therapeutics-market-100572

 

 

Detailed Table of Content:

 

  • Introduction
    • Research Scope
    • Market Segmentation
    • Research Methodology
    • Definitions and Assumptions
  • Executive Summary
  • Market Dynamics
    • Market Drivers
    • Market Restraints
    • Market Opportunities
  • Key Insights
    • Prevalence of Glioma by key Countries/Regions
    • Overview of Technological Advancements in the Glioma Therapy
    • key Industry Developments for key Countries/Regions -Mergers, Partnerships, & Acquisitions
    • Pipeline Analysis
  • Global Adult Malignant Glioma Therapeutics Market Analysis, Insights and Forecast, 2015-2026
    • Key Findings / Summary
    • Market Analysis, Insights and Forecast – By Type
      • Chemotherapy
      • Radiotherapy
      • Targeted Therapy
      • Others
    • Market Analysis, Insights and Forecast – By Application
      • Glioblastoma Multiforme
      • Anaplastic Astrocytoma
      • Anaplastic Oligodendroglioma
      • Others
    • Market Analysis, Insights and Forecast – By End User
      • Hospitals
      • Specialty Clinics
      • Cancer and Radiation Therapy Centers
      • Others
    • Market Analysis, Insights and Forecast – By Region
      • North America
      • Europe
      • Asia pacific
      • Rest of the World

TOC Continued…

 

Reasons to Purchase this Report:

 

  • Comprehensive analysis of the Adult Malignant Glioma Therapeutics Market growth drivers, obstacles, opportunities, and other related challenges.
  • Tracks the developments, such as new product launches, agreements, mergers and acquisitions, geographical expansions, and joint ventures.
  • Identifies market restraints and boosters.
  • Identifies all the possible segments present in the market to aid organizations in strategic business planning.

 

KEY QUESTIONS ANSWERED:

 

  • What are the key technological and Adult Malignant Glioma Therapeutics Market trends shaping the market?
  • What are the key opportunities in the market?
  • What are the key companies operating in the market?
  • Which company accounted for the highest market share?
  • Why Choose Fortune Business Insights?
  • What is the market size and growth rate of the global and regional market by various segments?
  • What is the market size and growth rate of the market for selective countries?
  • Which region or sub-segment is expected to drive the market in the forecast period?
  • What Factors are estimated to drive and restrain the Adult Malignant Glioma Therapeutics Market growth?
collect
0
avatar
ankit pittewar
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more